Cancer cell
Journal
Overview
publication venue for
-
ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis.
2024
-
Actomyosin-Mediated Cellular Tension Drives Increased Tissue Stiffness and β-Catenin Activation to Induce Epidermal Hyperplasia and Tumor Growth.
2024
-
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion.
2024
-
Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer.
2024
-
Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies..
42.
2024
-
Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors.
2024
-
Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas.
2024
-
Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma.
2024
-
Shifting the landscape: The role of IDH inhibitors in glioma cell fate.
2024
-
Having the cake and eating it? Clofazimine boosts immunotherapy while limiting side effects.
2024
-
Insights into how adeno-squamous transition drives KRAS inhibitor resistance..
42.
2024
-
ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis.
2024
-
SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions.
2024
-
SWI/SNF regulation of germinal center fate and lymphomagenesis.
2024
-
Chronic stress increases metastasis via neutrophil-mediated changes to the microenvironment.
2024
-
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade.
2024
-
Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer.
2024
-
A road map for the treatment of pediatric diffuse midline glioma.
2023
-
ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells.
2023
-
Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers.
2023
-
Cooperative CAR targeting to selectively eliminate AML and minimize escape.
2023
-
Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression..
41.
2023
-
Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling.
2023
-
MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma.
2023
-
Retraction Notice to: Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell Lymphomas..
41.
2023
-
RECISTv1.1 progression in oncology: Shades of gray.
2023
-
Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma..
41.
2023
-
Genomic mapping of metastatic organotropism in lung adenocarcinoma.
2023
-
Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade.
2023
-
IDH2 and TET2 mutations synergize to modulate T Follicular Helper cell functional interaction with the AITL microenvironment.
2023
-
Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia..
41.
2022
-
Hyaluronan driven by epithelial aPKC deficiency remodels the microenvironment and creates a vulnerability in mesenchymal colorectal cancer.
2022
-
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma..
40.
2022
-
Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors..
40.
2022
-
Ablation of the endoplasmic reticulum stress kinase PERK induces paraptosis and type I interferon to promote anti-tumor T cell responses.
2022
-
Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes..
40.
2022
-
Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence..
40.
2022
-
Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T cell responses..
40.
2022
-
An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes..
40.
2022
-
With one eye on the future..
40.
2022
-
Adoptive cell therapy with tumor-specific Th9 cells induces viral mimicry to eliminate antigen-loss-variant tumor cells..
39.
2021
-
Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer..
39.
2021
-
Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis..
39.
2021
-
Eradicating micrometastases with immune checkpoint blockade: Strike while the iron is hot..
39.
2021
-
Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity..
39.
2021
-
N6-Methyladenosine on mRNA facilitates a phase-separated nuclear body that suppresses myeloid leukemic differentiation..
39.
2021
-
Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy..
39.
2021
-
Cancer cells escape autophagy inhibition via NRF2-induced macropinocytosis..
39.
2021
-
A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation..
39.
2021
-
Women in cancer research and oncology..
39.
2021
-
Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients..
39.
2021
-
An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence..
39.
2021
-
SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19..
38.
2020
-
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma..
38.
2020
-
FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer..
38.
2020
-
Emergence of a High-Plasticity Cell State during Lung Cancer Evolution..
38.
2020
-
Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer..
38.
2020
-
Cell Lineage-Based Stratification for Glioblastoma..
38.
2020
-
PKCλ/ι Loss Induces Autophagy, Oxidative Phosphorylation, and NRF2 to Promote Liver Cancer Progression..
38.
2020
-
Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer..
38.
2020
-
Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response..
37.
2020
-
Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma..
37.
2020
-
Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation..
37.
2020
-
CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma..
37.
2020
-
Paradigms for Precision Medicine in Epichaperome Cancer Therapy..
36.
2019
-
ATRX In-Frame Fusion Neuroblastoma Is Sensitive to EZH2 Inhibition via Modulation of Neuronal Gene Signatures..
36.
2019
-
Dynamic Incorporation of Histone H3 Variants into Chromatin Is Essential for Acquisition of Aggressive Traits and Metastatic Colonization..
36.
2019
-
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies..
36.
2019
-
Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation..
36.
2019
-
The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression..
36.
2019
-
Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis..
35.
2019
-
Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF..
35.
2019
-
CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis..
35.
2019
-
CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response..
35.
2019
-
Increased Serine and One-Carbon Pathway Metabolism by PKCλ/ι Deficiency Promotes Neuroendocrine Prostate Cancer..
35.
2019
-
Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia..
35.
2019
-
A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion..
35.
2019
-
p62/SQSTM1 Fuels Melanoma Progression by Opposing mRNA Decay of a Selective Set of Pro-metastatic Factors..
35.
2018
-
Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway..
34.
2018
-
PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients..
34.
2018
-
Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer..
34.
2018
-
Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers..
34.
2018
-
HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis..
34.
2018
-
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers..
34.
2018
-
Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes..
34.
2018
-
Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations..
34.
2018
-
Non-conventional Inhibitory CD4+Foxp3-PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity..
33.
2018
-
Th9 Cells Represent a Unique Subset of CD4+ T Cells Endowed with the Ability to Eradicate Advanced Tumors..
33.
2018
-
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer..
33.
2018
-
Adipocyte p62/SQSTM1 Suppresses Tumorigenesis through Opposite Regulations of Metabolism in Adipose Tissue and Tumor..
33.
2018
-
ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia..
33.
2018
-
The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma..
33.
2018
-
The Integrated Genomic Landscape of Thymic Epithelial Tumors..
33.
2018
-
RHOA G17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis..
33.
2018
-
c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling..
33.
2018
-
Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer..
33.
2018
-
Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity..
33.
2017
-
Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms..
33.
2017
-
Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib..
32.
2017
-
Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance..
32.
2017
-
Stress-Activated NRF2-MDM2 Cascade Controls Neoplastic Progression in Pancreas..
32.
2017
-
SnapShot: Chronic Lymphocytic Leukemia..
32.
2017
-
Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML..
32.
2017
-
SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling..
31.
2017
-
Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis..
31.
2017
-
Molecular Checkpoint Decisions Made by Subverted Vascular Niche Transform Indolent Tumor Cells into Chemoresistant Cancer Stem Cells..
31.
2016
-
Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia..
30.
2016
-
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer..
30.
2016
-
p62/SQSTM1 by Binding to Vitamin D Receptor Inhibits Hepatic Stellate Cell Activity, Fibrosis, and Liver Cancer..
30.
2016
-
An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling..
30.
2016
-
EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis..
30.
2016
-
PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition..
30.
2016
-
Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2..
30.
2016
-
Epigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell Gene-Expression Program and Acute Leukemia Development..
30.
2016
-
p62, Upregulated during Preneoplasia, Induces Hepatocellular Carcinogenesis by Maintaining Survival of Stressed HCC-Initiating Cells..
29.
2016
-
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice..
29.
2016
-
A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity..
29.
2016
-
An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma..
29.
2016
-
Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells..
28.
2015
-
BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition..
28.
2015
-
CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms..
28.
2015
-
Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia..
28.
2015
-
Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups..
27.
2015
-
SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition..
27.
2015
-
Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms..
27.
2015
-
AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas..
27.
2015
-
Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma..
27.
2015
-
Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia..
27.
2015
-
Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo..
27.
2015
-
Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma..
27.
2015
-
Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia..
27.
2015
-
The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells..
27.
2015
-
Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ..
27.
2014
-
Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia..
26.
2014
-
The somatic genomic landscape of chromophobe renal cell carcinoma..
26.
2014
-
Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus..
26.
2014
-
Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis..
26.
2014
-
Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy..
25.
2014
-
MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia..
25.
2014
-
Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors..
25.
2014
-
Proteasome inhibitors evoke latent tumor suppression programs in pro-B MLL leukemias through MLL-AF4..
25.
2014
-
Angiocrine factors deployed by tumor vascular niche induce B cell lymphoma invasiveness and chemoresistance..
25.
2014
-
SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer..
24.
2013
-
A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells..
24.
2013
-
SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas..
23.
2013
-
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation..
23.
2013
-
SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism..
23.
2013
-
Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression..
23.
2013
-
Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF..
23.
2013
-
Suppression of miRNA-708 by polycomb group promotes metastases by calcium-induced cell migration..
23.
2013
-
Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists..
23.
2013
-
MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo..
22.
2012
-
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas..
22.
2012
-
Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas..
22.
2012
-
Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia..
22.
2012
-
Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma..
22.
2012
-
TGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma..
22.
2012
-
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression..
22.
2012
-
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia..
22.
2012
-
H2.0-like homeobox regulates early hematopoiesis and promotes acute myeloid leukemia..
22.
2012
-
The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma..
22.
2012
-
Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC..
21.
2012
-
Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells..
21.
2012
-
Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells..
21.
2012
-
WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing..
20.
2011
-
BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment..
20.
2011
-
Lung cancer signatures in plasma based on proteome profiling of mouse tumor models..
20.
2011
-
Tumor entrained neutrophils inhibit seeding in the premetastatic lung..
20.
2011
-
Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression..
20.
2011
-
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation..
20.
2011
-
Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia..
19.
2011
-
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer..
19.
2011
-
JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation..
19.
2011
-
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity..
19.
2011
-
BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma..
18.
2010
-
Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas..
18.
2010
-
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation..
18.
2010
-
FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis..
18.
2010
-
The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia..
18.
2010
-
4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors..
18.
2010
-
Integrative genomic profiling of human prostate cancer..
18.
2010
-
The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis..
17.
2010
-
PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas..
17.
2010
-
A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo..
17.
2010
-
Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence..
17.
2010
-
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate..
17.
2010
-
MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele..
17.
2010
-
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1..
17.
2010
-
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC..
17.
2010
-
DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia..
17.
2010
-
Latent bone metastasis in breast cancer tied to Src-dependent survival signals..
16.
2009
-
Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis..
16.
2009
-
Orai1 and STIM1 are critical for breast tumor cell migration and metastasis..
15.
2009
-
Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer..
14.
2008
-
Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis..
14.
2008
-
A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression..
14.
2008
-
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera..
13.
2008
-
Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development..
13.
2008
-
The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis..
13.
2008
-
The inhibition of tumor cell intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the tetraspanin CD151..
13.
2008
-
Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells..
13.
2008
-
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles..
12.
2007
-
FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia..
12.
2007
-
A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma..
12.
2007
-
Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis..
12.
2007
-
Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes..
12.
2007
-
Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy..
12.
2007
-
Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN..
11.
2007
-
Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs..
11.
2007
-
In vivo-restricted and reversible malignancy induced by human herpesvirus-8 KSHV: a cell and animal model of virally induced Kaposi's sarcoma..
11.
2007
-
Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies..
10.
2006
-
Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators..
10.
2006
-
The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor..
10.
2006
-
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines..
9.
2006
-
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients..
9.
2006
-
Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain..
9.
2006
-
The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells..
8.
2005
-
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis..
7.
2005
-
HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability..
6.
2004
-
Molecular characterization of the tumor microenvironment in breast cancer..
6.
2004
-
The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer..
5.
2004
-
Aminopeptidase A is a functional target in angiogenic blood vessels..
5.
2004
-
Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN..
5.
2004
-
Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors..
4.
2003
-
Myc-driven murine prostate cancer shares molecular features with human prostate tumors..
4.
2003
-
Second hand smoke stimulates tumor angiogenesis and growth..
4.
2003
-
2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF..
3.
2003
-
Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis..
3.
2003
-
Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/ KDR..
3.
2003
-
Gene expression correlates of clinical prostate cancer behavior..
1.
2002
-
Induction of ovarian cancer by defined multiple genetic changes in a mouse model system..
1.
2002
-
Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouraged..
26.
2014
-
Retraction. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis..
23.
2013
-
Epigenetic therapy leaps ahead with specific targeting of EZH2..
22.
2012
-
IDH1 mutations disrupt blood, brain, and barriers..
22.
2012
-
SnapShot: glioblastoma multiforme..
21.
2012
-
A TeNaCious foundation for the metastatic niche..
20.
2011
-
TORgeting oncogene addiction for cancer therapy..
9.
2006
-
Mitochondrial control of antigen presentation in cancer cells.
2023
-
Revealing de novo pyrimidine synthesis as a key vulnerability in brain tumors.
2022
-
Meningeal lymphatics prime tumor immunity in glioblastoma.
2021
-
CAR T Cells for Mantle Cell Lymphoma: Is it Time to Reshuffle the Deck?
2020
-
Cancer-Specific Splicing Changes and the Potential for Splicing-Derived Neoantigens.
2018
-
Targeting mRNA Decapping in AML.
2018
-
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.
2011
-
A catalytic role for proangiogenic marrow-derived cells in tumor neovascularization.
2008
-
AKT and cancer--is it all mTOR?
2006
-
Fertility outcomes post immune checkpoint inhibitor exposure.
2024
-
A Prostatic Intraepithelial Neoplasia-Dependent p27Kip1 Checkpoint Induces Senescence and Inhibits Cell Proliferation and Cancer Progression.
2024
-
Association of exercise with pan-cancer incidence and overall survival.
2024
-
Patterns of immune equilibrium and escape in indolent and progressing tumors.
2023
-
Clonal hematopoiesis and differential outcomes after immune checkpoint blockade.
2022
-
Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies.
2022
-
Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study.
2020
-
Melanoma models for the next generation of therapies.
2021
-
The Dual Roles of the Atypical Protein Kinase Cs in Cancer.
2019
-
Cytosolic DNA Sensing in Organismal Tumor Control.
2018
-
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies.
2018
-
Unique Metabolic Adaptations Dictate Distal Organ-Specific Metastatic Colonization.
2018
-
Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis.
2016
-
The journey from discoveries in fundamental immunology to cancer immunotherapy.
2015
-
Cancer stem cells: impact, heterogeneity, and uncertainty.
2012
-
Endostatin's endpoints-Deciphering the endostatin antiangiogenic pathway.
2004
-
Will mTOR inhibitors make it as cancer drugs?
2003
-
p27 as a target for cancer therapeutics.
2003
-
Vaccination against tumor neovascularization: Promise and reality.
2002
-
The EZH2 polycomb transcriptional repressor--a marker or mover of metastatic prostate cancer?
2002
-
Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia.
2002
-
Cancer Molecular Analysis Project: weaving a rich cancer research tapestry.
2002
-
Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics.
2002
-
Functional genomics and the breast cancer problem.
2002
-
The hallmarks of cancer immune evasion.
2024
-
Immune determinants of the pre-metastatic niche.
2023
-
Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors.
2019
-
Focus on breast cancer.
2002
Identity
ISO Abbreviation
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)